279 related articles for article (PubMed ID: 27329590)
1. Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma.
Benhamou Y; Picco V; Raybaud H; Sudaka A; Chamorey E; Brolih S; Monteverde M; Merlano M; Lo Nigro C; Ambrosetti D; Pagès G
Oncotarget; 2016 Jul; 7(28):44236-44251. PubMed ID: 27329590
[TBL] [Abstract][Full Text] [Related]
2. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
Bhuvaneswari R; Ng QF; Thong PS; Soo KC
Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells.
Lee JC; Chung LC; Chen YJ; Feng TH; Chen WT; Juang HH
Cancer Lett; 2015 May; 360(2):310-8. PubMed ID: 25721086
[TBL] [Abstract][Full Text] [Related]
4. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
[TBL] [Abstract][Full Text] [Related]
5. Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma.
Park J; Kim HJ; Kim KR; Lee SK; Kim H; Park KK; Chung WY
Oncotarget; 2017 Feb; 8(6):9079-9092. PubMed ID: 28030842
[TBL] [Abstract][Full Text] [Related]
6. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
7. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
[TBL] [Abstract][Full Text] [Related]
8. SOX4 expression is associated with treatment failure and chemoradioresistance in oral squamous cell carcinoma.
Yoon TM; Kim SA; Cho WS; Lee DH; Lee JK; Park YL; Lee KH; Lee JH; Kweon SS; Chung IJ; Lim SC; Joo YE
BMC Cancer; 2015 Nov; 15():888. PubMed ID: 26555193
[TBL] [Abstract][Full Text] [Related]
9. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
Cai Z; Hao XY; Liu FX
Arch Oral Biol; 2018 May; 89():20-25. PubMed ID: 29407635
[TBL] [Abstract][Full Text] [Related]
11. EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
Fletcher EV; Love-Homan L; Sobhakumari A; Feddersen CR; Koch AT; Goel A; Simons AL
Mol Cancer Res; 2013 Dec; 11(12):1574-84. PubMed ID: 24048704
[TBL] [Abstract][Full Text] [Related]
12. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
13. ZEB1 as an indicator of tumor recurrence for areca quid chewing-associated oral squamous cell carcinomas.
Ho CM; Hu FW; Lee SS; Shieh TM; Yu CH; Lin SS; Yu CC
J Oral Pathol Med; 2015 Oct; 44(9):693-8. PubMed ID: 25367287
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
[TBL] [Abstract][Full Text] [Related]
15. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
[TBL] [Abstract][Full Text] [Related]
16. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
Lu M; Wang C; Chen W; Mao C; Wang J
DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
[TBL] [Abstract][Full Text] [Related]
17. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone-related protein serves as a prognostic indicator in oral squamous cell carcinoma.
Lv Z; Wu X; Cao W; Shen Z; Wang L; Xie F; Zhang J; Ji T; Yan M; Chen W
J Exp Clin Cancer Res; 2014 Dec; 33(1):100. PubMed ID: 25539663
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-independent insulin-like growth factor binding protein 3 promotes cell migration and lymph node metastasis of oral squamous cell carcinoma cells by requirement of integrin β1.
Yen YC; Hsiao JR; Jiang SS; Chang JS; Wang SH; Shen YY; Chen CH; Chang IS; Chang JY; Chen YW
Oncotarget; 2015 Dec; 6(39):41837-55. PubMed ID: 26540630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
